NASDAQ: $AMGN
Amgen recently announced its financial results for the fourth quarter and the full year ended December 31, 2025. The company’s performance reflects ongoing strategic initiatives and the impact of its evolving portfolio in the biotechnology sector.
For the fourth quarter of 2025, Amgen reported total revenue of approximately $8.2 billion. This figure marks a modest increase compared to the same period in the previous year, demonstrating resilience in its established product lines amidst evolving market dynamics. The company’s earnings per share (EPS) for the quarter also showed positive momentum, reflecting effective operational management.
Looking at the full fiscal year 2025, Amgen generated total revenues reaching approximately $32.1 billion. This annual performance underscores the sustained demand across several key therapeutic areas. A significant driver of this success has been the continued strong uptake and performance of recent launches, which are contributing substantially to the top-line growth.
The company highlighted key operational achievements alongside its financial figures. Amgen emphasized its commitment to research and development, noting advancements in its pipeline across oncology, inflammation, and cardiovascular disease. Investment in innovation remains a core tenet of their long-term strategy, aiming to bring forward novel treatments for patients with serious illnesses.
Operating income for the full year 2025 stood at roughly $11.5 billion. This margin reflects disciplined expense management and efficient scaling of manufacturing and commercial operations. The reported operating income demonstrates Amgen’s ability to convert strong revenue performance into robust profitability.
During the earnings call accompanying the release, leadership provided forward-looking commentary, setting expectations for 2026. While specific guidance details are available in the official release, the tone suggested cautious optimism, balancing anticipated growth from key assets with potential competitive pressures and market access challenges.
Overall, the 2025 financial report presents a picture of a mature biotechnology leader continuing to deliver solid results while prioritizing pipeline progression. Investors and industry observers will be closely monitoring the execution of the strategic roadmap laid out for the coming year based on these strong year-end figures.